Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

Ranjan Mukherjee, Peter J. A. Davies, Diane L. Crombie, Eric D. Bischoff, Rosemary M. Cesario, Lily Jow, Lawrence G. Hamann, Marcus F. Boehm, Carl E. Mondon, Alex M. Nadzan, James R. Paterniti and Richard A. Heyman
Additional contact information
Ranjan Mukherjee: Ligand Pharmaceuticals
Diane L. Crombie: Ligand Pharmaceuticals
Eric D. Bischoff: Ligand Pharmaceuticals
Rosemary M. Cesario: Ligand Pharmaceuticals
Lily Jow: Ligand Pharmaceuticals
Lawrence G. Hamann: Ligand Pharmaceuticals
Marcus F. Boehm: Ligand Pharmaceuticals
Alex M. Nadzan: Ligand Pharmaceuticals
James R. Paterniti: Ligand Pharmaceuticals
Richard A. Heyman: Ligand Pharmaceuticals

Nature, 1997, vol. 386, issue 6623, 407-410

Abstract: Abstract Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription1–6. We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors? We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPARγ and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPARγ is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of non-insulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia. This antidiabetic activity can be further enhanced by combination treatment with PPARγ agonists, such as thiazolidinediones. These data suggest that the RXR:PPARγ heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance. Activation of the RXR:PPARγ dimer with rexinoids may provide a new and effective treatment for NIDDM.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/386407a0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:386:y:1997:i:6623:d:10.1038_386407a0

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/386407a0

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().